Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Med Hypotheses ; 145: 110305, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33032174

RESUMO

While COVID-19 continues to spread across the globe, diligent efforts are made to understand its attributes and dynamics to help develop treatment and prevention measures. The paradox pertaining to children being the least affected by severe illness poses exciting opportunities to investigate potential protective factors. In this paper, we propose that childhood vaccination against pertussis (whooping cough) might play a non-specific protective role against COVID-19 through heterologous adaptive responses in this young population. Pertussis is a vaccine-preventable infectious disease of the respiratory tract and it shares many similarities with COVID-19 including transmission and clinical features. Although pertussis is caused by a bacterium (Bordetella pertussis) while COVID-19 is a viral infection (SARS-CoV-2), previous data showed that cross-reactivity and heterologous adaptive responses can be seen with unrelated agents of highly divergent groups, such as between bacteria and viruses. While we build the arguments of this hypothesis on theoretical and previous empirical evidence, we also outline suggested lines of research from different fields to test its credibility. Besides, we highlight some concerns that may arise when attempting to consider such an approach as a potential public health preventive intervention against COVID-19.


Assuntos
COVID-19/epidemiologia , COVID-19/prevenção & controle , Toxina Pertussis/uso terapêutico , Vacina contra Coqueluche , Animais , Bordetella pertussis , Criança , Humanos , Imunidade Heteróloga/imunologia , Linfócitos/virologia , Modelos Teóricos , Medicina Preventiva/métodos , Saúde Pública , Sistema Respiratório/virologia
2.
Pharmeur Bio Sci Notes ; 2015: 82-96, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27506225

RESUMO

The 'International Workshop on Alternatives to the Murine Histamine Sensitization Test for Acellular Pertussis Vaccines: Progress and Challenges in the Replacement of HIST' was held on 24 August 2014, in Prague, Czech Republic, as a satellite meeting to the 9th World Congress on Alternatives and Animal Use in the Life Sciences. Participants discussed the progress and challenges associated with the development, validation, and implementation of in vitro assays as replacements for the histamine sensitisation test (HIST) for acellular pertussis vaccines. Discussions focused on the consistency approach, the necessary framework for regulatory acceptance of a harmonised method, and recent international efforts towards the development of in vitro assays to replace the HIST. Workshop participants agreed that acceptable alternatives to the HIST should be based on ADP ribosylation-mediated cell intoxication and therefore that the CHO cell clustering assay, which measures cell intoxication, should be further pursued and developed as a possible replacement for the HIST. Participants also agreed to continue ongoing multinational discussions involving national and international standardisation authorities to reach consensus and to organise collaborative studies in this context for assay characterisation and calibration of reference materials.


Assuntos
Histamina/administração & dosagem , Toxina Pertussis/uso terapêutico , Vacina contra Coqueluche/uso terapêutico , Vacinas Acelulares/uso terapêutico , Coqueluche/prevenção & controle , Animais , Células CHO , Cricetinae , Cricetulus , República Tcheca , Educação/métodos , Educação/tendências , Humanos , Camundongos , Coqueluche/diagnóstico
3.
Pharmeur Bio Sci Notes ; 2015: 97-114, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27506252

RESUMO

Current regulations for acellular pertussis (aP) vaccines require that they are tested for the presence of residual or reversion-derived pertussis toxin (PTx) activity using the mouse histamine sensitisation test (HIST). Although a CHO cell clustering assay can be used by manufacturers to verify if sufficient inactivation of the substance has occurred in-process, this assay cannot be used at present for the final product due to the presence of aluminium adjuvants which interfere with mammalian cell cultures. Recently, 2 modified CHO cell clustering assays which accommodate for the adjuvant effects have been proposed as alternatives to the HIST. These modified assays eliminate the adjuvant-induced cytotoxicity either through dilution of the vaccine (called the Direct Method) or by introducing a porous barrier between the adjuvant and the cells (the Indirect Method). Transferability and suitability of these methods for testing of products present on the European market were investigated during a collaborative study organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Thirteen laboratories participated in this study which included 4 aP-containing vaccines spiked by addition of PTx. This study also assessed the transferability of a standardised CHO cell clustering assay protocol for use with non-adjuvanted PTx preparations. Results showed that the majority of laboratories were able to detect the PTx spike in all 4 vaccines at concentrations of 4 IU/mL or lower using the Indirect Method. This sensitivity is in the range of the theoretical sensitivity of the HIST. The Direct Method however did not show the expected results and would need additional development work.


Assuntos
Química Farmacêutica/normas , Toxina Pertussis/isolamento & purificação , Toxina Pertussis/normas , Vacina contra Coqueluche/normas , Vacinas Acelulares/normas , Animais , Células CHO , Química Farmacêutica/métodos , Cricetinae , Cricetulus , Humanos , Camundongos , Toxina Pertussis/uso terapêutico , Vacina contra Coqueluche/uso terapêutico , Vacinas Acelulares/uso terapêutico
4.
Pharmeur Bio Sci Notes ; 2016: 151-170, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-28279256

RESUMO

The 'International Workshop on Alternatives to the Murine Histamine Sensitization Test for Acellular Pertussis Vaccines: In Search of Acceptable Alternatives to the Murine Histamine Sensitization Test (HIST): What is Possible and Practical?' was held on 4 and 5 March 2015 in London, United Kingdom. Participants discussed the results of the data generated from an international collaborative study (BSP114 Phase 2) sponsored by the European Directorate for the Quality of Medicines & Health Care (EDQM) to determine if a modified Chinese hamster ovary (CHO) cell-based clustering assay is a suitable alternative to replace HIST. Workshop participants agreed that protocol transferability demonstrated in the collaborative study indicates that a standardised CHO cell assay is adequate for measuring pure PTx in reference preparations. However, vaccine manufacturers would still need to demonstrate that the method is valid to detect or measure residual PTx in their specific adjuvanted products. The 2 modified CHO cell protocols included in the study (the Direct and the Indirect Methods) deserve further consideration as alternatives to HIST. Using the CHO cell assay, an in vitro alternative, for acellular pertussis (aP) vaccine batch release testing would reduce the number of animals used for aP vaccine safety testing. A strategic, stepwise adoption plan was proposed, in which the alternative test would be used for release purposes first, and then, once sufficient confidence in its suitable performance has been gained, its use would be extended to stability testing.


Assuntos
Alternativas aos Testes com Animais/normas , Química Farmacêutica/normas , Histamina/análise , Toxina Pertussis/análise , Alternativas aos Testes com Animais/métodos , Animais , Células CHO , Química Farmacêutica/métodos , Cricetinae , Cricetulus , Educação , Londres , Camundongos , Toxina Pertussis/uso terapêutico , Vacina contra Coqueluche/normas , Vacina contra Coqueluche/uso terapêutico , Coqueluche/prevenção & controle
5.
J Neurochem ; 135(5): 998-1006, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26365274

RESUMO

Increased calcium influx secondary to glutamate induced excitotoxicity initiates and potentiates devastating pathological changes following ischemic stroke. Pertussis toxin (PTx), a G-protein blocker, is known to suppress intracellular calcium accumulation. We hypothesize that PTx can protect against stroke by blocking calcium influx. In a permanent middle cerebral artery occlusion model, PTx (1000 ng) was given intraperitoneally 30 min after inducing stroke. Magnetic Resonance Imaging of perfusion and T2-weighted brain scans were obtained to evaluate cerebral blood flow (CBF) and infarct volume. Primary neuronal culture was used to test glutamate induced excitotoxicity and calcium influx. We established a non-linear exponential curve model to minimize variations in animal cerebrovasculature. A reduction of 40-60% in relative CBF was a critical window where infarct volume started to increase as rCBF reduced. PTx showed maximal effects in reducing infarct volume at this window. In vitro studies further demonstrated PTx increased neuronal cell survival by decreasing glutamate-induced calcium influx into neurons and preventing neurons from apoptosis. PTx salvages the ischemic penumbra by blocking calcium influx. This provides us a new mechanism upon which experimental therapies can be explored to treat ischemic stroke. In ischemic stroke, excessive glutamate binds to AMPA receptor that depolarizes calcium channel and/ or NMDA receptor. Both of them allow calcium to enter the cell. The overload of calcium triggers cellular cascade that includes Caspase activation and release, leading to pre-mature cell death. We have demonstrated that PTx, a G-protein inhibitor, blocks calcium entry which in turn prevents further cellular damage.


Assuntos
Cálcio/metabolismo , Circulação Cerebrovascular/efeitos dos fármacos , Infarto da Artéria Cerebral Média/complicações , Toxina Pertussis/uso terapêutico , Acidente Vascular Cerebral/tratamento farmacológico , Acidente Vascular Cerebral/etiologia , Animais , Apoptose/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Infarto Encefálico/tratamento farmacológico , Infarto Encefálico/etiologia , Caspase 3/metabolismo , Células Cultivadas , Córtex Cerebral/citologia , Modelos Animais de Doenças , Ácido Glutâmico/toxicidade , L-Lactato Desidrogenase/metabolismo , Imageamento por Ressonância Magnética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neurônios/efeitos dos fármacos , Acidente Vascular Cerebral/patologia
6.
Neuropharmacology ; 81: 1-5, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24486709

RESUMO

Pertussis toxin (PTx) has various effects in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). This study was designed to explore the protective effects of PTx of different doses and subunits. EAE model was induced with myelin oligodendrocyte glycoprotein (MOG35-55, 200 ug) plus complete Freund's adjuvant in 6-7 week-old female C57BL/6 mice. PTx reduced clinical deficits of EAE by 91.3%. This reduction in clinical deficits was achieved by attenuating demyelination by 75.5%. Furthermore, PTx reduced the lymphocyte infiltration, deactivated microglia activation and changed T cell profile by increasing T helper (type 1 and 2) and T regulatory cells.


Assuntos
Encefalomielite Autoimune Experimental/prevenção & controle , Microglia/efeitos dos fármacos , Toxina Pertussis/uso terapêutico , Linfócitos T/efeitos dos fármacos , Análise de Variância , Animais , Apresentação de Antígeno/efeitos dos fármacos , Proteínas de Ligação ao Cálcio/metabolismo , Proliferação de Células/efeitos dos fármacos , Citocinas/metabolismo , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Encefalomielite Autoimune Experimental/induzido quimicamente , Citometria de Fluxo , Fatores de Transcrição Forkhead/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Proteínas dos Microfilamentos/metabolismo , Glicoproteína Mielina-Oligodendrócito/toxicidade , Exame Neurológico , Fragmentos de Peptídeos/toxicidade , Toxina Pertussis/farmacologia , Baço/patologia , Fatores de Tempo
7.
J Cancer Res Clin Oncol ; 140(2): 291-301, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24337403

RESUMO

PURPOSE: Glioblastoma multiforme is the most frequent primary brain tumor, it has poor prognosis, and it remains refractory to current treatment. The success of temozolomide (TMZ) appears to be limited by the occurrence of chemoresistance. Recently, we report the use of pertussis toxin as adjuvant immunotherapy in a C6 glioma model; showing a decrease in tumoral size, it induced selective cell death in Treg cells, and it elicited less infiltration of tumoral macrophages. Here, we evaluated the cytotoxic effect of pertussis toxin in combination with TMZ for glioma treatment, both in vitro and in vivo RG2 glioma model. METHODS: We determined cell viability, cell cycle, apoptosis, and autophagy on treated RG2 cells through flow cytometry, immunofluorescence, and Western blot assays. Twenty-eight rats were divided in four groups (n = 7) for each treatment. After intracranial implantation of RG2 cells, animals were treated with TMZ (10 mg/Kg/200 µl of apple juice), PTx (2 µg/200 µl of saline solution), and TMZ + PTx. Animals without treatment were considered as control. RESULTS: We found an induction of apoptosis in around 20 % of RG2 cells, in both single treatments and in their combination. Also, we determined the presence of autophagy vesicles, without any modifications in the cell cycle in the TMZ - PTx-treated groups. The survival analyses showed an increase due to individual treatments; while in the group treated with the combination TMZ - PTx, this effect was enhanced. CONCLUSION: We show that the concomitant use of pertussis toxin plus TMZ could represent an advantage to improve the glioma treatment.


Assuntos
Antineoplásicos Alquilantes/uso terapêutico , Dacarbazina/análogos & derivados , Modelos Animais de Doenças , Glioma/tratamento farmacológico , Glioma/mortalidade , Toxina Pertussis/uso terapêutico , Animais , Protocolos de Quimioterapia Combinada Antineoplásica , Apoptose/efeitos dos fármacos , Autofagia , Western Blotting , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/patologia , Ciclo Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Dacarbazina/uso terapêutico , Glioma/patologia , Masculino , Ratos , Ratos Wistar , Taxa de Sobrevida , Temozolomida
8.
Neuroreport ; 24(9): 469-75, 2013 Jun 19.
Artigo em Inglês | MEDLINE | ID: mdl-23660634

RESUMO

We have reported earlier that pertussis toxin (PTx) attenuates the motor deficits in experimental autoimmune encephalomyelitis (EAE), an animal model for human multiple sclerosis. PTx protects neurons from inflammatory insults. Vascular endothelial growth factor (VEGF) is also neuroprotective. However, the effect of PTx on VEGF has never been studied. We investigated whether PTx modulates neuronal VEGF expression and how it affects the pathogenesis of EAE. EAE was induced by injecting myelin oligodendrocyte glycoprotein 35-55 peptides with adjuvants into C57BL/6 mice. Clinical scores of EAE were evaluated daily for 19 days. Brain and spinal cord samples were collected and assessed for inflammation and demyelination. VEGF, NeuN for neurons, and Caspase-3 for apoptosis were stained for localization using immunohistochemistry techniques, followed by western blot analysis for quantification. Primary neurons were cultured to assess the direct effect of PTx on neuronal VEGF expression. PTx treatment increases neuronal VEGF expression by up to ∼75% in vitro and ∼60% in vivo, preventing neurons from apoptosis. This leads to resolution in inflammation and remyelination and amendment in motor deficits. Our findings suggest that upregulation of endogenous neuronal VEGF by PTx protects motor deficits in EAE and it is a potential therapeutic option for multiple sclerosis.


Assuntos
Encefalomielite Autoimune Experimental/tratamento farmacológico , Encefalomielite Autoimune Experimental/metabolismo , Toxina Pertussis/uso terapêutico , Regulação para Cima/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Animais Recém-Nascidos , Células Cultivadas , Córtex Cerebral/citologia , Modelos Animais de Doenças , Encefalomielite Autoimune Experimental/induzido quimicamente , Camundongos , Camundongos Endogâmicos C57BL , Glicoproteína Mielina-Oligodendrócito/toxicidade , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Fragmentos de Peptídeos/toxicidade , Fator A de Crescimento do Endotélio Vascular/genética
9.
Immunology ; 119(2): 195-202, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16836650

RESUMO

In mice arthritis model induced by anti-type II collagen (CII) antibodies and lipopolysaccharide (LPS), most of cells that infiltrated into the joint space were neutrophils. To investigate the role of neutrophils in the pathogenesis of arthritis, we depleted the neutrophils in vivo by injection of the antibody against Gr-1 expressed mainly on neutrophils. The neutrophil depletion completely inhibited the arthritis development. Furthermore, neutrophil depletion in mice that had already developed arthritis ameliorated the disease. These results showed that neutrophils are indispensable not only for the development, but also for the maintenance of arthritis. Next, we tried to develop arthritis in C5-deficient mice to investigate the involvement of C5a, one of chemotactic factors for neutrophils. C5-deficient mice showed significant reduction in arthritis development in comparison with wild type mice. Injection of pertussis toxin (Ptx) into the mice, which inhibits the signals from the inhibitory G-protein coupled-receptors including the C5a receptor, suppressed the development of arthritis. Furthermore, Ptx also ameliorated the arthritis when injected into mice that had already developed the disease. These results suggest the important role of chemotactic factors involving C5a and inhibitory G-protein (Gi)-coupled receptors not only in the development, but also in the maintenance of arthritis.


Assuntos
Artrite Experimental/imunologia , Neutrófilos/imunologia , Animais , Anticorpos Monoclonais/imunologia , Artrite Experimental/etiologia , Artrite Experimental/patologia , Artrite Experimental/prevenção & controle , Colágeno Tipo II/imunologia , Complemento C5/deficiência , Complemento C5/imunologia , Lipopolissacarídeos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Infiltração de Neutrófilos/imunologia , Toxina Pertussis/farmacologia , Toxina Pertussis/uso terapêutico , Receptores de Quimiocinas/imunologia , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores Acoplados a Proteínas G/imunologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia , Membrana Sinovial/imunologia
10.
Pediatrics ; 111(5 Pt 1): 1042-5, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12728086

RESUMO

OBJECTIVE: To evaluate within the first 6 months of birth the immunogenicity of a 3-component acellular pertussis (aP) vaccine containing filamentous hemagglutinin (FHA), pertactine (PRN), and genetically detoxified pertussis toxin (PT) in infants who received a dose of vaccine at birth, in addition to the recommended schedule administered at 3, 5, and 11 months. Furthermore, we investigated the influence of maternal antibodies on aP vaccine response. METHODS: We used enzyme-linked immunosorbent assay to evaluate immunoglobulin G antibody levels in 45 infants immunized at birth and at 3, 5, and 11 months (group 1) and in 46 infants immunized at the ages of 3, 5, and 11 months (group 2). All mothers were also tested at delivery. RESULTS: At the age of 5 months the geometric mean titer of anti-PT, anti-FHA, and anti-PRN was significantly greater in group 1 (who had received 2 doses) than in group 2 (1 dose). At 6 months geometric mean titers were significantly higher in group 1 than in group 2 for anti-PRN and anti-FHA, whereas no significant differences were observed for anti-PT. CONCLUSIONS: Immunization at birth may be important for an earlier prevention of the pertussis disease in infants under 6 months, especially in Italy, where the recommended ages for aP vaccine administration are 3, 5, and 11 months.


Assuntos
Adesinas Bacterianas/imunologia , Anticorpos Antibacterianos/biossíntese , Proteínas da Membrana Bacteriana Externa/imunologia , Hemaglutininas/imunologia , Esquemas de Imunização , Toxina Pertussis/imunologia , Vacina contra Coqueluche/imunologia , Fatores de Virulência de Bordetella/imunologia , Adesinas Bacterianas/administração & dosagem , Adesinas Bacterianas/uso terapêutico , Adolescente , Adulto , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/administração & dosagem , Antígenos de Bactérias/imunologia , Antígenos de Bactérias/uso terapêutico , Proteínas da Membrana Bacteriana Externa/administração & dosagem , Proteínas da Membrana Bacteriana Externa/uso terapêutico , Bordetella pertussis/imunologia , Feminino , Hemaglutininas/administração & dosagem , Hemaglutininas/uso terapêutico , Humanos , Imunoglobulina G/biossíntese , Imunoglobulina G/sangue , Lactente , Recém-Nascido , Injeções Intramusculares , Itália , Masculino , Mães , Toxina Pertussis/administração & dosagem , Toxina Pertussis/uso terapêutico , Vacina contra Coqueluche/administração & dosagem , Vacina contra Coqueluche/uso terapêutico , Fatores de Virulência de Bordetella/administração & dosagem , Fatores de Virulência de Bordetella/uso terapêutico , Coqueluche/prevenção & controle
11.
Urol Res ; 30(3): 199-203, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12111185

RESUMO

The proliferation and migration of cells is a fundamental process for the metastasis of malignant tumour cells. In several in vitro studies, pertussis toxin (PTX) inhibited cell proliferation and cell motility in the human transitional cell carcinoma cell line J82. The present study investigated the effect of the intravesical application of PTX on the development of superficial bladder cancer in rats. We used the model of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN, 0.05% via drinking water x10 weeks) to induce superficial bladder carcinomas in 40 female rats. After 16 weeks the rats were treated in two groups with 0.4 ml PTX (1 microg/ml) or 0.4 ml phosphate buffered saline (PBS) by intravesical application (once a week for 10 weeks). In the 25th week urine cytology was determined and all rats were killed at week 26 followed by histological evaluation. In the control group, the urine cytology was positive for G2/G3 cells in ten of 17 rats. In the PTX group G2/G3 cells were determined in five of 20 rats ( P two tailed <0.05). Histopathologically 12 rats (71%) of the control group and 11 rats (55%) of the PTX group developed T1-T2 transitional-cell carcinomas. No local or systemic side effects were disclosed. PTX treatment reduces the development of G3 transitional cell carcinomas in rats and may represent a new approach for local therapy in superficial bladder cancer.


Assuntos
Carcinoma de Células de Transição/tratamento farmacológico , Toxina Pertussis/uso terapêutico , Neoplasias da Bexiga Urinária/tratamento farmacológico , Animais , Peso Corporal/efeitos dos fármacos , Butilidroxibutilnitrosamina , Carcinoma de Células de Transição/induzido quimicamente , Carcinoma de Células de Transição/patologia , Feminino , Toxina Pertussis/efeitos adversos , Ratos , Ratos Wistar , Neoplasias da Bexiga Urinária/induzido quimicamente , Neoplasias da Bexiga Urinária/patologia , Urina/citologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA